Legend Biotech Corp (LEGN) stock
LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$15.25−0.85 (-5.28%)
Close on Nov 20, 2026Market cap $2.82BP/E –Yield –
Legend Biotech net income
Net income is the profit left for shareholders after every expense, interest and tax.
Legend Biotech's net income for the twelve months ending Mar 31, 2025 was -$218.15M. For fiscal 2024 it was -$177.03M. The highest annual figure on record is -$2.78M in fiscal 2018.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -$177.03M | – |
| FY2023 | Dec 31, 2023 | -$518.25M | – |
| FY2022 | Dec 31, 2022 | -$446.35M | – |
| FY2021 | Dec 31, 2021 | -$403.58M | – |
| FY2020 | Dec 31, 2020 | -$266.37M | – |
| FY2019 | Dec 31, 2019 | -$101.59M | – |
| FY2018 | Dec 31, 2018 | -$2.78M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2025 | Mar 31, 2025 | -$100.92M | – |
| Q4 FY2024 | Dec 31, 2024 | $26.28M | – |
| Q3 FY2024 | Sep 30, 2024 | -$125.32M | – |
| Q2 FY2024 | Jun 30, 2024 | -$18.20M | – |
| Q1 FY2024 | Mar 31, 2024 | -$59.79M | – |
| Q4 FY2023 | Dec 31, 2023 | -$144.82M | – |
| Q3 FY2023 | Sep 30, 2023 | -$62.21M | – |
| Q2 FY2023 | Jun 30, 2023 | -$199.13M | – |
| Q1 FY2023 | Mar 31, 2023 | -$112.10M | – |
| Q4 FY2022 | Dec 31, 2022 | -$135.88M | – |
| Q3 FY2022 | Sep 30, 2022 | -$84.96M | – |
See a number that looks wrong?